Economic Burden of Multiple Sclerosis in Slovakia

Mária Pšenková, Stanislava Mackovičová, Alexander Palúch, Tatiana Foltánová, Lenka Petrová

Abstract


The disabling nature and lifelong impact of multiple sclerosis (MS) imposes considerable socioeconomic burden despite its relative low prevalence compared to other chronic diseases. This is the first study of MS in the Slovak Republic that provides information about healthcare and social expenditures including costs of productivity loss caused by reduced work capacity of patients with MS.

Retrospectively direct and indirect costs of MS were investigated by prevalence based “bottom-up” approach. The societal and health insurance perspective was used to perform the overall economic burden caused by MS in Slovakia. The human capital method was used for the calculation of indirect costs, as this is the most common method applied in published studies. As not all detailed data on expenditures were available, the missing data were collected in the retrospective patient research.

Total annual costs in 2010 for 6.100 dispensed patients with MS in Slovakia were €54.723.592. Indirect costs (€31.728.757) prevailed over direct costs (€22.994.834). The highest part of both costs were €25.207.512 and €12.641.052 for loss productivity due to patients sickness and invalidity pensions and disease-modifying drugs respectively. The average cost per patient independently of disease severity was €8.971.

MS causes a high economic burden, with a strong predominance of indirect costs. Documenting and quantifying this burden among patients with MS in different disease stages through cost-of-illness study can lead to better disease management and it can provide valuable information for future cost analysis and for decision-making process.


Keywords


Multiple Sclerosis. Costs. Slovakia

Full Text:

PDF

References


TaylorB, McDonald E, Fantino B. et al. The cost of multiple sclerosis in Australia //Journal of Clinical Neuroscience 2007 Jun; 14: 532–539.

Amato MP, Battaglia MA, Caputo D. et al. The cost of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy // Journal of Neurology. 2002 Feb; 249: 152–163.

O’Brien J, Ward AJ, Patrick AR, Caro J. Cost of managing an episode of relapse in multiple sclerosis in United States //BMC Health Services Research.2003 Sep; 3: 17.

World Health Organization. Multiple Sclerosis International Federation. “Atlas of Multiple Sclerosis Resources In The World 2008”. 20 Feb. 2011

The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial // Neurology. 1995Jul; 45(7): 1277–85.

The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis // Lancet. 1998 Nov; 352(9139):1498-504.

Li DKB, Paty DW, the UBC MS/MRI Analysis Research Group, the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis // Annals of Neurology. 1999; 46(2):197–206

The Once Weekly Interferon for MS Study Group (OWIMS). Evidence of interferon beta-1a dose response in relapsing-remitting MS. The OWIMS Study // Neurology.1999 Sep; 53(4):679–86.

Polman C, Barkhof F, Kappos L, et al. European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study // Multiple Sclerosis. 2003 Aug; 9: 342–48.

Koch-Henriksen N, Sørensen PS, Christensen T, etal. Danish Multiple Sclerosis Group:A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis //Neurology. 2006 Apr; 66(7): 1056-60.

Casado V, Martínez-Yélamos S, Martínez-Yélamos A, et al. Direct and indirect costs of Multiple Sclerosis in Baix Llobregat(Catalonia, Spain), according to disability //BMC Health Services Research. 2006Nov; 6:143.

Gonsette RE.Guidance on new therapies in MS patients // Lancet. 1996 Jul; 348: 136.

Larg A, Moss JR. Cost-of-Illness Studies. A Guide to Critical Evaluation //Pharmacoeconomics.2011 Aug; 29(8): 653-671.

Sobocki P, Pugliatti M, Lauer K, Kobelt G. Estimation of cost of MS in Europe: Extrapolations from a multinational cost study //Multiple Sclerosis. 2007Sep; 13(8):1054-64.

Henriksson F, Jönsson B. The Economic Cost of MultipleSclerosis in Sweden in 1994 // Pharmacoeconomics. 1998 May;13: 597-606.

Measure of Ministry of Health No. 07045/2003 – OAP about Price regulation and Price Regulation conditions of medical services that establish extent of price regulation in the health sector, Annex 4. Ministry of Health, Slovakia. 2003

Social Insurance, Bratislava. Statistics of health reasons of awarded disability pensions in 2010. Social Insurance Slovakia 2011

Social Insurance, Bratislava. Temporary productivity loss due to sickness and incident reasons health-insurance patients in Slovak republic with diagnosis G35 according to duration and age for year 2010. Social Insurance Slovakia 2011

Slovak Statistical Institute. The average monthly salary in the national economy in 2010.Slovak Statistical Institute 2011

Kobelt G, Berg J, Lindgren P, Fredrikson S, Jönsson B. Costs and quality of life of patients with multiple sclerosis in Europe // Journal of Neurology, Neurosurgery, and Psychiatry. 2006 Aug; 77: 918–926.

Blumhardt L,Wood C. The economics of multiple sclerosis: a cost of illness study // British Journal of Medical Economics. 10, 99–118 (1996)

Asche CV, Ho E, Chan B, Coyte PC. Economic consequences of MS for Canadians //Acta Neurologica Scandinavica. 1997 May; 95: 268-74

Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States //Neurology. 2006 Jun; 66(11): 1696-702.

Kobelt G, Berg J, Lindgren P, Jönsson B. Costs and quality of lifein multiple sclerosis in Europe: method of assessment and analysis // The European Journal of Health Economy. 2006 Sep; 7(Supp 2): 96-104.

Kobelt G, Texier-Richard B, Lindgren P. The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions //Multiple Sclerosis.2009 Jun; 5(6): 741-51.

Orlewska E, Mierzejewskia P, Zaborskic J, et al.A prospective study of the financial costs of multiple sclerosis at different stages of the disease //European Journal of Neurology. 2005 Jan; 12: 31–39




DOI: http://dx.doi.org/10.12955/emhpj.v3i0.346

Refbacks

  • There are currently no refbacks.


Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.